Exelixis, Inc.
EXELHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframePart of the healthcare sector, Exelixis, Inc. (EXEL) is listed under Biotechnology. The $12.69B market capitalization puts EXEL squarely in large-cap range for its industry. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Market Cap
$12.69B
Beta
0.39
P/E (TTM)
16.72
P/E (Fwd)
12.47
EPS (TTM)
$3.02
EPS (Fwd)
$4.05
ROE
41.0%
ROA
22.0%
Cash
$777.2M
Total Debt
$169.5M
Free CF
$629.1M
52W Change
17.7%
Annual Financials
Cash vs Debt
Exelixis, Inc. holds $777.2M in cash against $169.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $629.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 41.0% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 22.0% further supports the picture of efficient asset utilization. Revenue has grown from $1.61B (2022) to $2.32B (2025), reflecting a 44% increase over the period.
EXEL's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, EXEL has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Exelixis, Inc.'s trajectory.